Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The multiple myeloma idiotypic immunoglobulin, commonly known as the M-protein idiotype, represents the unique set of antigenic determinants located within the variable regions of the monoclonal antibody produced by a malignant plasma cell clone (Radl J., 1988). In the 5T2MM murine model, which serves as a highly relevant system for studying human multiple myeloma, this protein is expressed on the surface of tumor cells and secreted into the circulation, acting as a definitive tumor-specific antigen (Asosingh K., et al., 2000). Because the idiotype is unique to the malignant clone and absent from normal B cells, it is an ideal target for personalized immunotherapies, such as idiotype-pulsed dendritic cell vaccines or anti-idiotype antibodies, designed to elicit a specific cytotoxic T-lymphocyte response (Yi Q., et al., 2002). While the secreted M-protein contributes to disease pathology, including renal impairment, its role as a target focuses on the immune-mediated destruction of the underlying plasma cell malignancy (Bakkus MH., et al., 2003). Despite the high specificity of this approach, challenges remain regarding the logistical complexity of patient-specific vaccine production and the potential for tumor escape through the selection of idiotype-negative variants.
Induction of a specific immune response (cellular and humoral) against the unique variable regions (idiotypes) of the monoclonal immunoglobulin expressed by malignant plasma cells.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Multiple myeloma idiotypic immunoglobulin (M-protein idiotype) (M-protein idiotype).